ClinicalTrials.gg
RecruitingNCT05808634Updated Sep 25, 2025

Phase 1 Study Evaluating BA3182 in Patients With Advanced Adenocarcinoma.

A Phase 1 interventional study of BA3182 in Advanced Adenocarcinoma, sponsored by BioAtla, Inc.. Recruiting at 9 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-09-25.

Sponsored by BioAtla, Inc. · Phase 1, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Jul 2023; still recruiting 3 years 4 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
168
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 2,057 studies in Neoplasm Metastasis with a site in United States — 344 open to participants now, 544 under way, 58 of them phase 3. Neoplasm Metastasis · United States.

Planned enrollment
348th of 1,866
168 · median 43
Started
2023
with 101 others
Phase 1
710 of 2,057
127 open now
Primary completion
2028-09
later than 419 of 542 live
Registered
1,772nd of 2,057
by date

Among the 2,057 studies in Neoplasm Metastasis with a site in United States, this one is the 348th largest by planned enrollment of the 1,866 interventional ones that give a count, is one of 102 that started in 2023, is one of 710 in phase 1, reaches primary completion later than 419 of the 542 other live ones, and was the 1,772nd registered.

Neoplasm Metastasis

4,052 studies on the registry are indexed under Neoplasm Metastasis; 891 are open to participants now.

Browse Neoplasm Metastasis studies →

Open to participants now

344 of the 2,057 studies in Neoplasm Metastasis with a site in United States are open now. Recruiting first, the newest first:

339 more — sign in →

All 344 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 692 Neoplasm Metastasis studies recruiting now, 539 (78%) set no upper age limit and 96 (14%) stop at 75 or younger; 47 take children under 18; 18 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 2,057 studies in Neoplasm Metastasis with a site in United States, or all of them as a file.
02

Study summary

The objective of this study is to assess safety and efficacy of BA3182 in Advanced Adenocarcinoma

Read the detailed description

This is a multi-center, open-label, Phase 1 study designed to evaluate the safety, tolerability, PK, immunogenicity, and antitumor activity of BA3182 in patients with advanced adenocarcinoma.

03

Conditions studied

  • Advanced Adenocarcinoma

Keywords

  • Advanced
  • Metastatic
  • Cancer
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • or cytologically confirmed locally advanced unresectable or adenocarcinoma
  • Age ≥ 18 years
  • Adequate renal function
  • Adequate liver function
  • Adequate hematological function
  • Have an (ECOG) performance status of 0 or 1.

Exclusion criteria

Exclusion Criteria:

  • Patients must not have cardiac disease.
  • Patients must not have known non-controlled .
  • Patients must not have active disease or a documented history of autoimmune disease.
  • Patients must not have a history of ≥ Grade 3 allergic reactions to mAb therapy as wellas known or suspected allergy or intolerance to any agent given during this study.
  • Patients must not incomplete recovery from the effects of major surgery or significant traumatic injury before the first dose of study treatment.
  • Patients must not have known (HIV) infection, active and/or .
  • Patients must not be women who are pregnant or breast feeding.
Terms in these criteria, in plain language(9)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
168 participants (estimated)

Study arms

  • Experimental
    BA3182

    All Patients will receive BA3182

    Drug: BA3182

Interventions

  • DrugBA3182

    Conditionally active biologic (CAB)-bispecific T-cell engager antibody construct targeting EpCAM

06

What researchers measure

Primary outcomes

  1. Part 1: Assess dose limiting toxicity as defined in the protocol

    Phase 1 Part 1: Safety Profile of BA3182

    Time frame: Up to 24 months

  2. Part 1: Assess maximum tolerated dose as defined in the protocol

    Phase 1 Part 1: Safety Profile of BA3182

    Time frame: Up to 24 months

  3. Part 2: Confirmed overall response rate (ORR) per RECIST v1.1

    Phase 1 Part 2: Antitumor activity of BA3182

    Time frame: Up to 24 months

Secondary outcomes

  1. Confirmed overall response rate (ORR) per RECIST v1.1

    Phase 1 Part 1: Antitumor activity of BA3182

    Time frame: Up to 24 months

  2. Confirmed best overall response best overall response (BOR)

    Phase 1: Antitumor activity of BA3182

    Time frame: Up to 24 months

  3. Confirmed duration of response (DOR)

    Phase 1: Antitumor activity of BA3182

    Time frame: Up to 24 months

  4. Confirmed progression-free survival (PFS)

    Phase 1: Antitumor activity of BA3182

    Time frame: Up to 24 months

  5. Confirmed disease control rate (DCR)

    Phase 1: Antitumor activity of BA3182

    Time frame: Up to 24 months

  6. Confirmed time to response (TTR)

    Phase 1: Antitumor activity of BA3182

    Time frame: Up to 24 months

  7. Confirmed overall survival (OS)

    Phase 1: Antitumor activity of BA3182

    Time frame: Up to 24 months

  8. Confirmed percent change from baseline in target lesion sum of diameters.

    Phase 1: Antitumor activity of BA3182

    Time frame: Up to 24 months

  9. Area under the plasma concentration versus time curve (AUC)

    Phase 1: Pharmacokinetics of BA3182

    Time frame: Up to 24 months

  10. Peak Plasma Concentration (Cmax) Phase 1: Pharmacokinetics

    Phase 1: Pharmacokinetics of BA3182

    Time frame: Up to 24 months

  11. Incidence of anti-drug antibody (ADAs) to BA3182 Phase 1: Pharmacokinetics Phase 1: Immunogenicity

    Phase 1: Immunogenicity of BA3182

    Time frame: Up to 24 months

  12. Incidence of neutralizing antibodies (nAbs) to BA3182.

    Phase 1: Immunogenicity of BA3182

    Time frame: Up to 24 months

07

Study locations

9 of 9 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jul 2023 (actual). Primary completion is estimated for Sep 2028, 62 months after the start.

Of 289 industry-sponsored phase 1 interventional studies under Neoplasm Metastasis, half reached primary completion within 48 months of starting (the median), counting those still running; a quarter within 28 and three quarters within 75. This study's planned 62 months is above that.

Counting every sponsor, half of 498 studies reached it within 54 months; a quarter within 33 and three quarters within 83.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 17, 2023
First posted
Apr 11, 2023
StartActual
Jul 14, 2023
Primary completionEst.
Sep 15, 2028
CompletionEst.
Sep 15, 2028
Last update
Sep 25, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 25, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05808634
Lead sponsor
BioAtla, Inc.
Responsible party
Sponsor
First posted
Apr 11, 2023
Start date
Jul 14, 2023
Primary completion
Sep 15, 2028 (estimated)
Completion
Sep 15, 2028 (estimated)
Last update
Sep 25, 2025

Study contacts

BioAtla Medical Affairs
Contact
medicalaffairs@bioatla.com
858-558-0708 ext. 3333

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion